It is possible that obesity or other components of the metabolic syndrome per se lead to upregulation of the chemokine and osteopontin pathways even without NAFLD and this question is being addressed by our group. The gene discussed is SPP1; the disease is metabolic dysfunction-associated steatotic liver disease.